Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Several technologies for hemoglobinopathies are being transferred to commercial partners
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Subscribe To Our Newsletter & Stay Updated
